Augmentation of rat skin flap viability by relaxin-expressing adenovirus

Wound Repair and Regeneration

Volumn 19, Issue 6, 2011, Pages 709-717

  Lee, Won Jai ^a   Yun, Chae Ok ^a,b   Yun, In Sik ^a   Kim, Yong Oock ^a   Choi, Il Kyu ^a,b   Yun, Tae Jin ^a,b   Rah, Dong Kyun ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BETA GALACTOSIDASE; CD31 ANTIGEN; PHOSPHATE BUFFERED SALINE; RELAXIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DOPPLER FLOWMETRY; GENE EXPRESSION; GRAFT PERFUSION; GRAFT SURVIVAL; MALE; MICROCIRCULATION; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN FLAP;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC VECTORS; GRAFT SURVIVAL; MALE; MICROCIRCULATION; RATS; RATS, SPRAGUE-DAWLEY; RELAXIN; SKIN; SURGICAL FLAPS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80155141690     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2011.00733.x     Document Type: Article

References (29)

1. Kerrigan CL,. Skin flap failure: pathophysiology. Plast Reconstr Surg 1983; 72: 766-777.
2. Maldonado C, Stadelmann WK, Ramirez S, Quan E, Barker JH,. Preconditioning of latissimus dorsi muscle flaps with monophosphoryl lipid A. Plast Reconstr Surg 2003; 111: 267-274. (Pubitemid 36015189)
3. Seify H, Bilkay U, Jones G,. Improvement of TRAM flap viability using human VEGF-induced angiogenesis: a comparative study of delay techniques. Plast Reconstr Surg 2003; 112: 1032-1039. (Pubitemid 38251797)
4. Khan A, Ashrafpour H, Huang N, Neligan PC, Kontos C, Zhong A, Forrest CR, Pang CY,. Acute local subcutaneous VEGF165 injection for augmentation of skin flap viability: efficacy and mechanism. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1219-1229. (Pubitemid 39391069)
5. Huang N, Khan A, Ashrafpour H, Neligan PC, Forrest CR, Kontos CD, Pang CY,. Efficacy and mechanism of adenovirus-mediated VEGF-165 gene therapy for augmentation of skin flap viability. Am J Physiol Heart Circ Physiol 2006; 291: H127-137.
6. Hopper RA, Forrest CR, Xu H, Zhong A, He W, Rutka J, Neligan P, Pang CY,. Role and mechanism of PKC in ischemic preconditioning of pig skeletal muscle against infarction. Am J Physiol Regul Integr Comp Physiol 2000; 279: R666-676.
7. Hong JP, Kwon H, Chung YK, Jung SH,. The effect of hyperbaric oxygen on ischemia-reperfusion injury: an experimental study in a rat musculocutaneous flap. Ann Plast Surg 2003; 51: 478-487. (Pubitemid 37420647)
8. Pellitteri PK, Kennedy TL, Youn BA,. The influence of intensive hyperbaric oxygen therapy on skin flap survival in a swine model. Arch Otolaryngol Head Neck Surg 1992; 118: 1050-1054.
9. Nakagawa A, Makino H, Aoki M, Miyake T, Shiraya S, Nakamura T, Ogihara T, Kimata Y, Morishita R,. Improvement of survival of skin flaps by combined gene transfer of hepatocyte growth factor and prostacyclin synthase. J Gene Med 2007; 9: 1087-1094. (Pubitemid 350286414)
10. Lubiatowski P, Goldman CK, Gurunluoglu R, Carnevale K, Siemionow M,. Enhancement of epigastric skin flap survival by adenovirus-mediated VEGF gene therapy. Plast Reconstr Surg 2002; 109: 1986-1993. (Pubitemid 34492428)
11. Samuel CS, Hewitson TD, Unemori EN, Tang ML,. Drugs of the future: the hormone relaxin. Cell Mol Life Sci 2007; 64: 1539-1557. (Pubitemid 46954152)
12. Sherwood OD,. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25: 205-234. (Pubitemid 38501394)
13. Samuel CS, Hewitson TD,. Relaxin in cardiovascular and renal disease. Kidney Int 2006; 69: 1498-1502.
14. Dschietzig T, Bartsch C, Baumann G, Stangl K,. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 2006; 112: 38-56. (Pubitemid 44301484)
15. Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, Mak J, Grove BH,. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reprod 1999; 14: 800-806. (Pubitemid 29131267)
16. Unemori EN, Lewis M, Constant J, Arnold G, Grove BH, Normand J, Deshpande U, Salles A, Pickford LB, Erikson ME, Hunt TK, Huang X,. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Rep Regen 2000; 8: 361-370.
17. Bani D, Bigazzi M, Masini E, Bani G, Sacchi TB,. Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Lab Invest 1995; 73: 709-716.
18. Bani D, Maurizi M, Bigazzi M,. Original article: relaxin reduces the number of circulating platelets and depresses platelet release from megakaryocytes: studies in rats. Platelets 1995; 6: 330-335.
19. Novak J, Rubin JP, Matthews J, Conrad KP,. Vascular endothelial growth factor (VEGF) is a new player in the slow relaxin, (Rlx) vasodilatory pathway. Faseb J 2007; 21: A1371-A.
20. Kim J, Cho JY, Kim JH, Jung KC, Yun CO,. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002; 9: 725-736. (Pubitemid 34971303)
21. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO,. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006; 98: 1482-1493. (Pubitemid 44605593)
22. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M,. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810. (Pubitemid 26187479)
23. Zheng Y, Yi C, Xia W, Ding T, Zhou Z, Han Y, Guo S,. Mesenchymal stem cells transduced by vascular endothelial growth factor gene for ischemic random skin flaps. Plast Reconstr Surg 2008; 121: 59-69.
24. Kim J, Lee Y, Kim H, Huang J, Yoon AR, Yun C,. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006; 98: 1482-1493. (Pubitemid 44605593)
25. Flotte TR, Ng P, Dylla DE, McCray PB, Wang G, Kolls JK, Hu J., Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther: J Am Soc Gene Ther 2007; 15: 229-241. (Pubitemid 46111871)
26. St George JA,. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003; 10: 1135-1141. (Pubitemid 36896588)
27. Ghali S, Dempsey MP, Jones DM, Grogan RH, Butler PE, Gurtner GC,. Plastic surgical delivery systems for targeted gene therapy. Ann Plast Surg 2008; 60: 323-332.
28. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, Ferris B, Sanborn T, Isom P, Ferris B, Sanborn T, Isom OW, Crystal RG, Rosengart TK,. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998; 27: 699-709. (Pubitemid 28201761)
29. Failli P, Nistri S, Quattrone S, Mazzetti L, Bigazzi M, Sacchi TB, Bani D,. Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. Faseb J 2002; 16: 252-254.